Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23174375 | 1.00 | GCK (0.39) | GCKRORCMEN1LMNAMAPT | |
| SCHEMBL24759583 | 1.00 | GCK (0.39) | GCKRORCMEN1LMNAMAPT | |
| SCHEMBL23193417 | 1.00 | GCK (0.39) | GCKRORCMEN1LMNAMAPT | |
| SCHEMBL23174379 | 0.92 | RORC (0.47) | GCKRORCMEN1LMNAMAPT | |
| SCHEMBL23174411 | 0.92 | RORC (0.47) | GCKRORCMEN1LMNAMAPT | |
| SCHEMBL23174378 | 0.92 | RORC (0.47) | GCKRORCMEN1LMNAMAPT | |
| SCHEMBL23174358 | 0.90 | LMNA (0.40) | GCKRORCLMNA | |
| SCHEMBL23174401 | 0.90 | LMNA (0.40) | GCKRORCLMNA | |
| SCHEMBL23174359 | 0.90 | LMNA (0.40) | GCKRORCLMNA | |
| SCHEMBL23193397 | 0.88 | RORC (0.41) | GCKRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI LITEDD CO., LTD. (CN) | 2022-12-22 | — | — | US | disclosed |
| WO-2021063362-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| WO-2021063362-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402867-A1 | SULFO-SUBSTITUTED BIARYL COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | RORB, RORA, RORC | GCK 3895/4885RORC 3/4885MEN1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.